NMOSD

In this discussion, the pair of neurologists explore the latest drug development and ongoing clinical trials for MOGAD, a rare neuroimmune disorder. [WATCH TIME: 4 minutes]

In this segment, Bennett and Greenberg explore the diagnosis, acute treatment, and long-term management of MOGAD, highlighting current therapies and ongoing research. [WATCH TIME: 8 minutes]

In this episode, Greenberg and Bennett provide some perspective on the fluidity of MOGAD diagnosis and how it could potentially change over time as more is understood about neuroimmune disorders. [WATCH TIME: 5 minutes]

In this segment, the duo of neurologists provided a number of informative considerations treating clinicians should take when diagnosing MOGAD, emphasizing careful testing and interpretation of data in this complex process. [WATCH TIME: 4 minutes]

For the majority of patients who were either aquaporin-4-antibody seropositive or seronegative, rituximab was the first disease-modifying therapy administered for neuromyelitis optica spectrum disorder.

The analysis revealed a significant link between the proportion of AQP4 antibody-positive cases and a higher female-to-male sex ratio in NMOSD.

Patients with myelin oligodendrocyte glycoprotein IgG-associated disease with severer attacks had higher C5b-9 levels than those with milder attacks.

Research indicated that up to 46% of patients diagnosed with presumed autoimmune limbic encephalitis tested negative for all currently identified central nervous system antigens.

Recent findings showed that treatment with satralizumab was likely associated with a reduction in the concomitant use of immunosuppressive therapies in neuromyelitis optica spectrum disorder.

The study highlights a dramatic decrease in income for patients following disease onset and a significantly higher proportion of them requiring social welfare jobs or disability pensions.

Most relapses occurred before patients resumed immunotherapy after giving birth, suggesting that continued immunosuppression during pregnancy might help prevent attacks.

The study found a 98% agreement between treating physicians’ initial diagnoses and the new MOGAD criteria.

Investigators found that in melanomas in particular, interleukin-6 blockade seems to be effective in the management of immune-related adverse events from immune checkpoint inhibitors.

LETM and AQP4-IgG seropositivity were strong predictors of spinal movement disorders, while MOG-IgG and African American race are protective factors.

The study highlights tocilizumab's potential benefits and safety, even during SARS-CoV-2 infection.

A recent study showed significant retinal damage in patients with double-antibody seronegative neuromyelitis optica spectrum disorders following optic neuritis.

Benjamin Greenberg, MD, a pediatric neurologist at the University of Texas Southwestern Medical Center, provided commentary on a recently initiated online program dedicated to empowering those affected by rare neuroimmune disorders.

A recent study identified limitations in the Expanded Disability Status Score scale's ability to capture full disability spectrum in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein-antibody-associated disease.

Intravenous methylprednisolone combined with plasma exchange/immunoadsorption achieved better and continuous improvement than IVMP alone

Patients treated with at least 12.5 mg/day of oral prednisone for at least 3 months had an 88% reduction in the risk of relapse compared with those who did not receive this regimen.

The clinical research director of the UCSF Multiple Sclerosis Center discussed findings from the end-of-study analysis assessing inebilizumab which revealed a significant reduction in attack rates among patients with NMOSD over time. [WATCH TIME: 3 minutes]

The clinical research director of the UCSF Multiple Sclerosis Center provided an overview of the phase 2/3 N-Momentum study assessing the efficacy of inebilizumab in patients with neuromyelitis optica spectrum disorder. [WATCH TIME: 5 minutes]

The professor of neurology at the University of Virginia talked about the improvement and areas of unmet need in the diagnosis and treatment for neuromyelitis optica spectrum disorder. [WATCH TIME: 6 minutes]

The professor of neurology at Mayo Clinic talked about how MOG antibody-associated disease can be diagnosed through specific antibody tests, highlighting its distinct clinical and MRI features. [WATCH TIME: 4 minutes]

The associate professor of neurology at Harvard Medical School talked about results from a recent study that evaluated the efficacy of inebilizumab versus rituximab in treating NMOSD.